Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2004

View Archived Issues

NPS Pharmaceuticals reviews progress of late-stage product candidates

Fazaclo receives FDA approval

AEterna expands pipeline through Zentaris research collaborations

Neuroprotective effects of SUN-N8075 shown in animal models of stroke

Antiplatelet and neuroprotective effects of FK-419 shown in vitro and in vivo

Antares' topical oxybutynin product successfully completes phase I trial

Launch of new Salagen dosage

Serono gains access to ProMetic's protein purification technology

Clinical evidence of the efficacy of Caduet in hypertension and high cholesterol

Promising effects found with ABT-578-eluting stents in de novo coronary lesions

An oral insulin spray enhances the postprandial efficacy of oral hypoglycemic drugs

SOM-230 reported effective in reducing serum GH levels of acromegalic patients

Efficacy and safety of tacrolimus in rheumatoid arthritis unresponsive to DMARDs

New MMP/TACE inhibitors in early development at BMS

BMS scientists design novel beta-secretase inhibitors

New cannabinoid CB1 antagonists and their use as antiobesity agents

Two novel series of sodium channel blockers and their use in pain, neuronal ischemia, etc.

Novel antiangiogenic tyrosine kinase inhibitor claimed by Boehringer Ingelheim

Merck patent covers new cannabinoid CB1 inhibitors and their use

Encouraging preclinical results with novel anti-anthrax antibody

Targeting beta-amyloid aggregation for Alzheimer therapy

Hart-Scott-Rodino wait over for Neurocrine purchase of indiplon rights

Maxim reacquires rights to MX-2105 series

Atrix signs feasibility agreement for development of Aventis compounds

European orphan drug status for AMT's LPL gene therapy product

Corgenix Medical and Genesis Bioventures sign merger agreement

MLN-2704 selected for CMA Pilot 2 Program

tgAAC94 enters phase I rheumatoid arthritis study